Flotation

Ozon to float in $990m IPO
Sistema invested $67.5m in the e-commerce platform developer alongside an upsized initial public offering in which it floated above its range.
Antengene accelerates to $360m flotation
The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.
GenCell powers its way to public markets
TDK Ventures, Paz Oil and Landa Ventures-backed hydrogen and ammonia fuel cell technology developer raised $60.7m in an Israel flotation.
NeoGames passes IPO level
William Hill sold $11.5m shares in the $81.7m initial public offering but remains the lottery software producer's largest shareholder.
Supcon to succeed with $268m IPO
Chint, Sinopec, Intel, Wanxiang and Lenovo-backed process automation technology producer Supcon has priced an offering on Shanghai's Star Exchange.
JW Therapeutics gets $300m in IPO
WuXi AppTec and Juno Therapeutics' joint cancer immunotherapy venture has listed on the Hong Kong Stock Exchange.
SQZ Bio squeezes on to NYSE
The AIG, Illumina, Alphabet and Orient Life-backed cell therapy developer priced its shares at the bottom of the range to raise $70.6m.
Lufax loops on to public markets
Ping An's financial services spinoff raised $2.36bn in a US initial public offering that represented an exit for Bank of China, Cofco, SBI and several investment banks.

Other News

Galecto gathers $85m in initial public offering
Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.
Ant Group's IPO to achieve $34bn raise
Several corporates are set to exit the financial services provider in the biggest IPO in history, while parent company Alibaba will buy about $7.5bn of shares.
Aligos accesses public markets with $150m
Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.
Eargo steers its way to $141m IPO
Nan Fung-backed hearing aid producer Eargo's shares opened at double its IPO price after it floated above its range.
Miniso manages $608m in IPO
The Tencent-backed retail chain floated well above its range in New York and its shares have risen some 40% post-IPO.
Spruce ups IPO to $104m
Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

Editor's Picks

Lufax loops on to public markets
Ping An's financial services spinoff raised $2.36bn in a US initial public offering that represented an exit for Bank of China, Cofco, SBI and several investment banks.
Galecto gathers $85m in initial public offering
Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.
Ant Group's IPO to achieve $34bn raise
Several corporates are set to exit the financial services provider in the biggest IPO in history, while parent company Alibaba will buy about $7.5bn of shares.
Aligos accesses public markets with $150m
Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.
test reg

Login